Create a narrative

Harrow Community

NasdaqGM:HROW Community

1 Narratives written by author
0 Comments on narratives written by author
9 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 8 Analysts

Rising Specialty Ophthalmics And Biosimilars Will Open New Markets

Key Takeaways Accelerating demand for Harrow's specialty eye drugs and expansion into new treatment areas support strong, sustained top-line and margin growth. Improved patient access, partnerships, and integration of new innovative products strengthen competitive positioning and enable outsized earnings growth.

US$59.78

FV

35.1% undervalued

38.81%

Revenue growth p.a.

0

0

6

1 day ago